瓣中瓣经导管主动脉瓣置换术：最新综述
Valve-in-Valve TAVR: State-of-the-Art Review.
作者信息
Edelman J James, Khan Jaffar M, Rogers Toby, Shults Christian, Satler Lowell F, Ben-Dor I Itsik, Waksman Ron, Thourani Vinod H
机构信息
1 Department of Cardiac Surgery, MedStar Heart and Vascular Institute, Georgetown University School of Medicine, Washington, DC, USA.
2 Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
出版信息
Innovations (Phila). 2019 Aug;14(4):299-310. doi: 10.1177/1556984519858020. Epub 2019 Jul 22.
An increasing number of surgically implanted bioprostheses will require re-intervention for structural valve deterioration. Valve-in-valve transcatheter aortic valve replacement (ViV TAVR) has become an alternative to reoperative surgery, currently approved for high-risk and inoperable patients. Challenges to the technique include higher rates of prosthesis-patient mismatch and coronary obstruction, compared to native valve TAVR. Herein, we review results of ViV TAVR and novel techniques to overcome the aforementioned challenges.
越来越多通过手术植入的生物假体将因瓣膜结构退化而需要再次干预。瓣中瓣经导管主动脉瓣置换术（ViV TAVR）已成为再次手术的替代方案，目前已被批准用于高危和无法进行手术的患者。与原生瓣膜TAVR相比，该技术面临的挑战包括人工瓣膜与患者不匹配及冠状动脉阻塞的发生率更高。在此，我们回顾ViV TAVR的结果以及克服上述挑战的新技术。
Zotero 插件